Suppr超能文献

人表皮生长因子受体2(HER-2)过表达与结直肠癌患者生存率的关系:一项荟萃分析

HER-2 overexpression and survival in colorectal cancer: a meta-analysis.

作者信息

Li Chao, Liu Da-ren, Ye Long-yun, Huang Ling-na, Jaiswal Sanjay, Li Xiao-wen, Wang Hou-hong, Chen Li

机构信息

Department of Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310021, China.

出版信息

J Zhejiang Univ Sci B. 2014 Jun;15(6):582-9. doi: 10.1631/jzus.B1300258.

Abstract

OBJECTIVE

Numerous studies examining the relationship between human epidermal growth factor receptor 2 (HER-2) overexpression and survival in patients with colorectal cancer (CRC) have yielded controversial results. We therefore performed a meta-analysis more precisely to estimate its prognostic value.

METHODS

Published studies investigating the effect of HER-2 overexpression on CRC survival were identified; the hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were pooled in terms of disease-specific or overall survival.

RESULTS

Eleven studies were included in the meta-analysis. The pooled data showed that HER-2 overexpression was negatively related to CRC survival (HR=1.10, 95% CI: 0.77-1.44). Subgroup analyses regarding test method and study quality also demonstrated little association between HER-2 overexpression and CRC survival (HR=0.89, 95% CI: 0.50-1.29; HR=0.90, 95% CI: 0.43-1.37, respectively).

CONCLUSIONS

Regardless of several limitations, our study suggested that HER-2 overexpression probably had little impact on CRC survival.

摘要

目的

众多研究探讨了人类表皮生长因子受体2(HER-2)过表达与结直肠癌(CRC)患者生存率之间的关系,但其结果存在争议。因此,我们进行了一项荟萃分析,以更精确地评估其预后价值。

方法

检索已发表的研究,这些研究调查了HER-2过表达对CRC生存的影响;根据疾病特异性生存或总生存汇总风险比(HR)及其相应的95%置信区间(95%CI)。

结果

荟萃分析纳入了11项研究。汇总数据显示,HER-2过表达与CRC生存呈负相关(HR=1.10,95%CI:0.77-1.44)。关于检测方法和研究质量的亚组分析也表明,HER-2过表达与CRC生存之间几乎没有关联(HR分别为0.89,95%CI:0.50-1.29;HR为0.90,95%CI:0.43-1.37)。

结论

尽管存在一些局限性,但我们的研究表明,HER-2过表达可能对CRC生存影响不大。

相似文献

1
HER-2 overexpression and survival in colorectal cancer: a meta-analysis.
J Zhejiang Univ Sci B. 2014 Jun;15(6):582-9. doi: 10.1631/jzus.B1300258.
2
The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies.
Tumour Biol. 2014 Nov;35(11):10799-804. doi: 10.1007/s13277-014-2376-0. Epub 2014 Jul 31.
3
Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis.
Asian Pac J Cancer Prev. 2014;15(14):5551-6. doi: 10.7314/apjcp.2014.15.14.5551.
6
Prognostic value of LGR5 in colorectal cancer: a meta-analysis.
PLoS One. 2014 Sep 5;9(9):e107013. doi: 10.1371/journal.pone.0107013. eCollection 2014.
8
High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.
World J Gastroenterol. 2017 Jul 21;23(27):5018-5033. doi: 10.3748/wjg.v23.i27.5018.
9
The prognostic value of proliferating cell nuclear antigen expression in colorectal cancer: A meta-analysis.
Medicine (Baltimore). 2018 Dec;97(50):e13752. doi: 10.1097/MD.0000000000013752.
10
The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis.
Int J Clin Oncol. 2017 Aug;22(4):749-757. doi: 10.1007/s10147-017-1106-1. Epub 2017 Mar 25.

引用本文的文献

2
HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study.
Asian Pac J Cancer Prev. 2024 Jun 1;25(6):2023-2032. doi: 10.31557/APJCP.2024.25.6.2023.
3
HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration.
Biomedicines. 2023 Oct 25;11(11):2889. doi: 10.3390/biomedicines11112889.
5
6
HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer.
Cancer Manag Res. 2021 Apr 20;13:3443-3454. doi: 10.2147/CMAR.S297596. eCollection 2021.
9
Expression of COX-2 and HER-2 in colorectal cancer and their correlation.
World J Gastroenterol. 2015 May 28;21(20):6206-14. doi: 10.3748/wjg.v21.i20.6206.
10
HER2 expression in gastric and oesophageal cancer: a meta-analytic review.
J Gastrointest Oncol. 2015 Apr;6(2):143-54. doi: 10.3978/j.issn.2078-6891.2014.107.

本文引用的文献

1
Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.
Clin Med Insights Oncol. 2013;7:41-51. doi: 10.4137/CMO.S10811. Epub 2013 Feb 21.
2
Frequency of HER-2 positivity in rectal cancer and prognosis.
Am J Surg Pathol. 2013 Apr;37(4):522-31. doi: 10.1097/PAS.0b013e318272ff4d.
4
Advanced HER2-positive gastric cancer: current and future targeted therapies.
Crit Rev Oncol Hematol. 2013 Mar;85(3):350-62. doi: 10.1016/j.critrevonc.2012.08.008. Epub 2012 Sep 26.
7
Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer.
Cancer Invest. 2011 Aug;29(7):456-9. doi: 10.3109/07357907.2011.590569. Epub 2011 Jun 22.
8
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
10
Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases.
Ann Surg Oncol. 2010 Jun;17(6):1555-63. doi: 10.1245/s10434-009-0897-3. Epub 2010 Jan 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验